Literature DB >> 19185864

Association of apolipoprotein A5 concentration with serum insulin and triglyceride levels and coronary artery disease in Korean men.

Yae Jung Hyun1, Yangsoo Jang, Jey Sook Chae, Ji Young Kim, Jean Kyung Paik, So Yeon Kim, Ju Young Yang, Jose M Ordovas, Young Guk Ko, Jong Ho Lee.   

Abstract

OBJECTIVE: Whereas the relation between apolipoprotein A5 (APOA5) gene polymorphisms and triglycerides (TG) levels is well established, the associations between apoA5 concentrations, TG and coronary artery disease (CAD) remain controversial. Therefore, we investigated these relations in the setting of a case-control study involving Korean males.
METHODS: ApoA5, TG, insulin, free fatty acid (FFA) and lipoprotein profiles were determined using a cross-sectional design in 777 healthy controls and 367 CAD patients.
RESULTS: Plasma apoA5 concentration was lower in CAD patients than controls (192.7+/-5.2 vs. 237.2+/-3.7ng/ml, P<0.001). Values in the second and top tertiles of apoA5 were associated with a decreased odds ratio (OR) for CAD when compared with values in the bottom tertile; OR for apoA5 top tertile was 0.33 (95% CI, 0.23-0.47) in the age- and BMI-adjusted model and 0.35 (95% CI, 0.23-0.56) following additional adjustments for smoking, drinking status, blood pressure, TG and HDL-cholesterol. After adjustment for age and BMI, plasma apoA5 concentration was negatively correlated with serum TG (r=-0.188, P<0.001) and insulin (r=-0.185, P<0.001) in normotriglyceridemic controls (TG<150mg/dL, n=509) whereas apoA5 was positively correlated with serum TG in hypertriglyceridemic controls (TG> or =150mg/dL, n=268) (r=0.246, P<0.001) and total CAD patients (r=0.177, P<0.01). Regardless of TG levels and CAD status, apoA5 concentration was positively correlated with HDL-cholesterol and FFA levels.
CONCLUSIONS: Our data supports an inverse association between plasma apoA5 concentrations and CAD risk, probably due to the observed negative correlations of apoA5 with TGs and insulin, although these correlations were affected by TG levels.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19185864      PMCID: PMC4426969          DOI: 10.1016/j.atherosclerosis.2008.12.035

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  30 in total

1.  Dietary intake of n-6 fatty acids modulates effect of apolipoprotein A5 gene on plasma fasting triglycerides, remnant lipoprotein concentrations, and lipoprotein particle size: the Framingham Heart Study.

Authors:  Chao-Qiang Lai; Dolores Corella; Serkalem Demissie; L Adrienne Cupples; Xian Adiconis; Yueping Zhu; Laurence D Parnell; Katherine L Tucker; Jose M Ordovas
Journal:  Circulation       Date:  2006-04-24       Impact factor: 29.690

2.  A sandwich enzyme-linked immunosorbent assay for human plasma apolipoprotein A-V concentration.

Authors:  Mitsuaki Ishihara; Takeshi Kujiraoka; Tadao Iwasaki; Makoto Nagano; Mayumi Takano; Jun Ishii; Masahiro Tsuji; Hajime Ide; Irina P Miller; Norman E Miller; Hiroaki Hattori
Journal:  J Lipid Res       Date:  2005-06-16       Impact factor: 5.922

3.  The apolipoprotein A-V genotype and plasma apolipoprotein A-V and triglyceride levels: prospective risk of type 2 diabetes. Results from the Northwick Park Heart Study II.

Authors:  P J Talmud; J A Cooper; H Hattori; I P Miller; G J Miller; S E Humphries
Journal:  Diabetologia       Date:  2006-08-18       Impact factor: 10.122

4.  Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase.

Authors:  Martin Merkel; Britta Loeffler; Malte Kluger; Nathalie Fabig; Gesa Geppert; Len A Pennacchio; Alexander Laatsch; Joerg Heeren
Journal:  J Biol Chem       Date:  2005-03-17       Impact factor: 5.157

5.  Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration.

Authors:  H N van der Vliet; M G Sammels; A C Leegwater; J H Levels; P H Reitsma; W Boers; R A Chamuleau
Journal:  J Biol Chem       Date:  2001-09-27       Impact factor: 5.157

6.  Genetic variations of apolipoprotein A5 gene is associated with the risk of coronary artery disease among Chinese in Taiwan.

Authors:  Lung-An Hsu; Yu-Lin Ko; Chi-Jen Chang; Chiao-Feng Hu; Semon Wu; Ming-Sheng Teng; Chun-Li Wang; Wan-Jing Ho; Yu-Shien Ko; Tsu-Shiu Hsu; Ying-Shiung Lee
Journal:  Atherosclerosis       Date:  2005-07-27       Impact factor: 5.162

7.  Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia.

Authors:  Frank G Schaap; Melchior C Nierman; Jimmy F P Berbée; Hiroaki Hattori; Philippa J Talmud; Stefan F C Vaessen; Patrick C N Rensen; Robert A F M Chamuleau; Jan Albert Kuivenhoven; Albert K Groen
Journal:  J Lipid Res       Date:  2006-07-21       Impact factor: 5.922

8.  Postprandial increase of plasma apoAV concentrations in Type 2 diabetic patients.

Authors:  Valérie Pruneta-Deloche; Gabriel Ponsin; Laure Groisne; Jamila Fruchart-Najib; Michel Lagarde; Philippe Moulin
Journal:  Atherosclerosis       Date:  2005-02-17       Impact factor: 5.162

9.  Polymorphism in the promoter region of the apolipoprotein A5 gene is associated with an increased susceptibility for coronary artery disease.

Authors:  Csaba Szalai; Márton Keszei; Jenõ Duba; Zoltán Prohászka; Gergely Tibor Kozma; Albert Császár; Sándor Balogh; Zsuzsa Almássy; George Fust; Antal Czinner
Journal:  Atherosclerosis       Date:  2004-03       Impact factor: 5.162

10.  ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis.

Authors:  Frank G Schaap; Patrick C N Rensen; Peter J Voshol; Carlos Vrins; Hendrik N van der Vliet; Robert A F M Chamuleau; Louis M Havekes; Albert K Groen; Ko Willems van Dijk
Journal:  J Biol Chem       Date:  2004-04-16       Impact factor: 5.157

View more
  7 in total

Review 1.  Apolipoprotein A5 fifteen years anniversary: Lessons from genetic epidemiology.

Authors:  Jaroslav A Hubacek
Journal:  Gene       Date:  2016-08-02       Impact factor: 3.688

2.  Common functional variants of APOA5 and GCKR accumulate gradually in association with triglyceride increase in metabolic syndrome patients.

Authors:  Ferenc Hadarits; Péter Kisfali; Márton Mohás; Anita Maász; Balázs Duga; Ingrid Janicsek; István Wittmann; Béla Melegh
Journal:  Mol Biol Rep       Date:  2011-06-04       Impact factor: 2.316

3.  Association of Serum Apolipoprotein A5 Concentration with Nonalcoholic Fatty Liver Disease in Ningbo, China.

Authors:  Xiao Liu; Ping Xu; Xueping Tao; Wenli Li; Qiongyi Hong; Qunfen Cao
Journal:  Contrast Media Mol Imaging       Date:  2022-07-08       Impact factor: 3.009

Review 4.  The Roles of Fatty Acids and Apolipoproteins in the Kidneys.

Authors:  Xiaoyue Pan
Journal:  Metabolites       Date:  2022-05-20

Review 5.  The paradox of ApoA5 modulation of triglycerides: evidence from clinical and basic research.

Authors:  Mahdi Garelnabi; Kenton Lor; Jun Jin; Fei Chai; Nalini Santanam
Journal:  Clin Biochem       Date:  2012-09-19       Impact factor: 3.281

6.  Consumption of whole grains and legumes modulates the genetic effect of the APOA5 -1131C variant on changes in triglyceride and apolipoprotein A-V concentrations in patients with impaired fasting glucose or newly diagnosed type 2 diabetes.

Authors:  Ryungwoo Kang; Minjoo Kim; Jey Sook Chae; Sang-Hyun Lee; Jong Ho Lee
Journal:  Trials       Date:  2014-04-01       Impact factor: 2.279

7.  Effects of a 3-year dietary intervention on age-related changes in triglyceride and apolipoprotein A-V levels in patients with impaired fasting glucose or new-onset type 2 diabetes as a function of the APOA5 -1131 T > C polymorphism.

Authors:  Minjoo Kim; Jey Sook Chae; Miri Kim; Sang-Hyun Lee; Jong Ho Lee
Journal:  Nutr J       Date:  2014-04-28       Impact factor: 3.271

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.